Description

CJC-1295 With DAC 2mg – Long-Acting GHRH Research Peptide

CJC-1295 With DAC 2mg is a synthetic growth hormone-releasing hormone (GHRH) analogue investigated in scientific research involving pituitary endocrine regulation, growth hormone secretion, IGF-1 signalling and peptide pharmacokinetics.

The defining feature of CJC-1295 with DAC is its Drug Affinity Complex modification, designed to enable binding to circulating albumin. This molecular engineering approach distinguishes it from shorter-acting GHRH analogues and from the compound commonly marketed as CJC-1295 without DAC or Modified GRF (1-29).

Published human studies have investigated the long-acting CJC-1295 construct and reported sustained changes in circulating growth hormone and IGF-1 concentrations. However, these studies do not establish CJC-1295 as an effective treatment for obesity, muscle growth, athletic performance or ageing-related conditions.

CJC-1295 With DAC 2mg is therefore relevant to laboratory research involving peptide modification, albumin binding, GHRH receptor biology and the regulation of endocrine signalling.

What Is CJC-1295 With DAC?

CJC-1295 with DAC is a synthetic analogue of the biologically active N-terminal region of human growth hormone-releasing hormone.

The underlying peptide contains 29 amino acid residues and selected substitutions intended to alter its chemical and biological properties.

Unlike Modified GRF 1-29, CJC-1295 with DAC contains an additional albumin-binding chemical group.

This modification is designed to form a covalent association with circulating albumin, a major protein present in blood plasma.

Albumin binding is important because it can alter a peptide’s distribution and elimination characteristics.

In controlled human research, the DAC-modified compound demonstrated prolonged systemic exposure compared with the short duration associated with native GHRH.

CJC-1295 With DAC 2mg Product Specifications

• Product Name: CJC-1295 With DAC 2mg
• Alternative Name: CJC-1295 DAC
• Classification: Synthetic long-acting GHRH analogue
• Peptide Backbone: Modified 29-residue GHRH fragment
• Peptide Length: 29 amino acid residues
• DAC Modification: Present
• DAC Function: Albumin-binding chemical modification
• Reference Molecular Weight: Approximately 3,647 g/mol for the commonly described DAC-modified construct
• Labelled Quantity: 2mg
• Research Target: Growth Hormone-Releasing Hormone Receptor (GHRHR)
• Research Category: Endocrinology and peptide pharmacokinetics
• Research Focus: Growth hormone secretion, IGF-1 signalling and albumin binding
• Reported Human Research Half-Life: Approximately 5.8–8.1 days in the studied preparation
• Purity: Requires batch-specific verification
• Salt Form: Confirm with manufacturer
• Physical Form: Confirm with manufacturer
• Storage: Follow verified manufacturer instructions
• Intended Use: Laboratory research only

The reference molecular weight is not a substitute for analytical confirmation. The exact molecular identity, counterions, water content and formulation components of a commercial CJC-1295 DAC preparation must be established through supplier documentation.

Understanding the Molecular Structure of CJC-1295 DAC

CJC-1295 with DAC is based on a modified growth hormone-releasing hormone peptide backbone.

The underlying 29-residue structure is related to the active N-terminal portion of naturally occurring GHRH.

Selected amino acid substitutions distinguish the modified backbone from the corresponding native GHRH fragment.

The most important additional feature is the DAC group, which is designed to bind circulating albumin.

This chemical modification distinguishes the DAC form from Modified GRF 1-29.

Researchers should verify the complete peptide sequence, attachment position and structure of the DAC group rather than relying on the product name alone.

How Does CJC-1295 With DAC Work?

CJC-1295 with DAC is associated with activation of the growth hormone-releasing hormone receptor.

The GHRH receptor is expressed by growth hormone-producing somatotroph cells in the anterior pituitary gland.

Activation of this receptor is associated with intracellular cyclic AMP signalling and regulation of growth hormone secretion.

The DAC modification affects the compound’s pharmacokinetic behaviour by supporting its association with circulating albumin.

Published human research has demonstrated that the investigated long-acting CJC-1295 preparation can produce sustained increases in circulating growth hormone and IGF-1.

However, prolonged hormone elevation is not equivalent to established improvements in body composition, physical performance or clinical health outcomes.

Scientific Research Into CJC-1295 With DAC

1. Growth Hormone Secretion Research

Growth hormone is produced by somatotroph cells located in the anterior pituitary gland.

Its secretion is influenced by growth hormone-releasing hormone, somatostatin and other physiological signals.

CJC-1295 with DAC has been investigated because of its ability to produce prolonged growth hormone responses in controlled experimental settings.

A published study involving healthy adults reported sustained elevations in circulating growth hormone following exposure to the long-acting peptide.

These results support the compound’s endocrine activity but do not establish its effectiveness for treating disease or improving athletic performance.

2. IGF-1 Signalling Research

Insulin-like growth factor 1, commonly abbreviated IGF-1, is involved in growth-related cellular signalling and endocrine regulation.

Growth hormone contributes to the regulation of circulating IGF-1 concentrations.

In human research involving CJC-1295 with DAC, investigators reported prolonged elevations in IGF-1 following exposure to the studied compound.

These findings are relevant to understanding the relationship between GHRH receptor activation, growth hormone secretion and downstream endocrine responses.

However, increases in IGF-1 are biological measurements rather than proof of improved muscle development or metabolic health.

3. Albumin-Binding Research

Albumin is a major circulating protein involved in maintaining plasma oncotic pressure and transporting various molecules.

The DAC modification in CJC-1295 was designed to support binding to albumin.

This approach is relevant to pharmaceutical research because albumin association can alter the duration of exposure to certain compounds.

Investigations of CJC-1295 with DAC have contributed to understanding how chemical modification can influence peptide pharmacokinetics.

Albumin-binding behaviour depends on the exact molecular structure and should not be assumed for peptides lacking the DAC group.

4. Peptide Pharmacokinetics

Pharmacokinetics describes how a compound is absorbed, distributed and eliminated within a biological system.

CJC-1295 with DAC has been investigated in controlled human pharmacokinetic studies.

In the studied healthy adults, researchers estimated an elimination half-life of approximately 5.8 to 8.1 days.

This prolonged exposure was associated with the albumin-binding properties of the DAC-modified construct.

However, the reported half-life is a finding from particular experimental preparations and participants.

It does not independently establish the pharmacokinetic characteristics of every commercially labelled CJC-1295 DAC product.

5. Growth Hormone Pulsatility Research

Growth hormone is normally released in pulses rather than at a constant rate.

This pulsatile pattern is influenced by hypothalamic and pituitary signalling.

A published human study investigated growth hormone secretion patterns during sustained stimulation by CJC-1295.

The researchers reported that pulsatile secretion persisted despite prolonged stimulation by the long-acting analogue.

These findings are relevant to the study of endocrine rhythms and growth hormone regulatory mechanisms.

They do not establish that CJC-1295 provides long-term clinical benefits.

6. GHRH Receptor Signalling

The growth hormone-releasing hormone receptor is a G-protein-coupled receptor involved in pituitary endocrine regulation.

Activation of the receptor is associated with cyclic AMP and protein kinase A signalling pathways.

These intracellular mechanisms contribute to growth hormone production and secretion.

CJC-1295 with DAC provides an experimental model for investigating sustained GHRH receptor stimulation.

The compound’s prolonged systemic exposure makes its research profile different from that of native GHRH and Modified GRF 1-29.

7. Peptide Engineering and Drug Affinity Complex Research

Peptide engineering involves modifying molecular structures to investigate stability, receptor activity and pharmacokinetic behaviour.

CJC-1295 with DAC is an example of a synthetic peptide containing both sequence modifications and an albumin-binding chemical group.

Researchers have investigated this approach to understand how molecular design can influence exposure duration.

However, increased persistence in circulation may also prolong biological effects and potential adverse reactions.

Pharmacokinetic engineering therefore requires careful safety evaluation.

8. Endocrine Feedback Regulation

Growth hormone and IGF-1 operate within a complex endocrine regulatory system.

Feedback mechanisms influence the secretion of growth hormone and related hypothalamic signals.

Research involving sustained GHRH receptor stimulation can help scientists investigate these interactions.

CJC-1295 with DAC has been studied because of its prolonged influence on circulating growth hormone and IGF-1.

However, long-term endocrine effects remain insufficiently characterised.

9. Human Clinical Research

Published human studies of CJC-1295 with DAC have investigated pharmacokinetics, hormone responses and short-term tolerability.

In a 2006 investigation, healthy adult volunteers participated in controlled trials measuring growth hormone, IGF-1 and drug exposure.

Researchers reported prolonged hormonal responses and an estimated elimination half-life of several days.

Another study examined the persistence of pulsatile growth hormone secretion during exposure to the long-acting compound.

These studies provide direct human evidence of endocrine activity.

However, they do not establish long-term safety, treatment effectiveness or benefits for obesity, muscle growth or ageing.

CJC-1295 With DAC vs Without DAC

CJC-1295 with DAC and CJC-1295 without DAC are chemically distinct compounds.

• With DAC: Contains an albumin-binding modification designed to prolong systemic exposure.
• Without DAC: Commonly refers to Modified GRF 1-29, which lacks the albumin-binding modification.
• Peptide Backbone: Both are related to a modified 29-residue GHRH fragment.
• Reference Molecular Weight: The DAC form is commonly reported at approximately 3,647 g/mol, while the without-DAC peptide is approximately 3,368 g/mol.
• Human Pharmacokinetic Evidence: The frequently cited 5.8–8.1-day half-life relates to the DAC-modified compound.
• Product Identification: Both require verification of the actual supplied molecular structure.

The two forms should not be described as interchangeable.

CJC-1295 With DAC vs Sermorelin

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone.

CJC-1295 with DAC contains modifications that distinguish it from sermorelin.

Most importantly, CJC-1295 DAC includes an albumin-binding chemical group absent from sermorelin.

The compounds therefore differ in molecular identity and pharmacokinetic characteristics.

Clinical findings involving one compound should not automatically be applied to the other.

CJC-1295 With DAC vs Ipamorelin

CJC-1295 with DAC and ipamorelin are synthetic research peptides associated with growth hormone-related pathways.

However, their receptor targets differ.

CJC-1295 with DAC is a GHRH analogue associated with GHRH receptor signalling.

Ipamorelin is a growth hormone secretagogue associated with the ghrelin receptor pathway.

The compounds also differ substantially in molecular structure and pharmacokinetic evidence.

Findings involving ipamorelin cannot establish the safety or effectiveness of CJC-1295 with DAC.

CJC-1295 With DAC and Muscle Growth Research

CJC-1295 with DAC is sometimes discussed in connection with muscle growth because of its ability to influence growth hormone and IGF-1 concentrations.

However, hormone elevation does not establish clinically meaningful increases in muscle mass or strength.

There is insufficient reliable clinical evidence that CJC-1295 with DAC improves muscle development, exercise recovery or athletic performance.

Such claims should not be presented as proven product benefits.

CJC-1295 With DAC and Weight Management

CJC-1295 with DAC is not an established weight-loss treatment.

Its principal research associations involve GHRH receptor signalling, growth hormone secretion and peptide pharmacokinetics.

Although growth hormone participates in metabolic regulation, there is insufficient clinical evidence that CJC-1295 with DAC produces sustained fat loss or treats obesity.

It should not be described as a proven fat-burning or appetite-suppressing compound.

Understanding the CJC-1295 With DAC 2mg Label

The 2mg designation refers to the labelled quantity of research material.

It does not represent a recommended human dose or independently establish purity, sterility or biological activity.

Researchers should verify whether the stated quantity refers to the complete DAC-modified peptide and whether the supplied material contains counterions or other formulation components.

Batch-specific analytical documentation is necessary to establish the product’s actual specifications.

CJC-1295 With DAC 2mg Research Quality and Documentation

Important considerations when evaluating CJC-1295 DAC research material include:

• Verification of the complete modified GHRH peptide sequence
• Confirmation that the DAC modification is present
• Identification of the DAC attachment structure
• Verification of the supplied molecular form
• Batch-specific certificate of analysis
• Appropriate analytical purity testing
• Mass spectrometry or another suitable identity method
• Confirmation of the labelled 2mg quantity
• Identification of counterions and formulation components
• Assessment of peptide-related impurities
• Manufacturer and batch traceability
• Verified packaging specifications
• Product-specific storage and stability information
• Clearly stated research-use classification

These records help distinguish verified DAC-modified research material from products identified only by commercial naming conventions.

Storage and Handling of CJC-1295 With DAC

CJC-1295 with DAC research material should be stored according to verified manufacturer instructions.

Storage requirements depend on the peptide’s molecular form, formulation, packaging and stability characteristics.

Researchers should not assume that all CJC-1295 DAC products have identical storage conditions or shelf-life characteristics.

Laboratory handling should follow applicable safety documentation and institutional procedures.

CJC-1295 DAC Safety and Scientific Limitations

CJC-1295 with DAC is an investigational peptide with limited human clinical safety data.

Published short-term human studies reported adverse effects including injection-site reactions and other systemic symptoms.

Regulatory safety assessments have also identified concerns involving increased heart rate, systemic vasodilatory reactions, peptide impurities and potential immunogenicity.

Long-term safety, particularly following repeated exposure, has not been established.

The compound’s prolonged pharmacokinetic profile may extend both intended biological activity and unwanted effects.

Research-grade CJC-1295 DAC should not be assumed suitable for human administration.

CJC-1295 with DAC is not an established approved treatment for obesity, muscle growth, anti-ageing or other medical conditions in the United Kingdom.

This information is intended for scientific and educational purposes only and does not provide medical advice, human dosing recommendations or administration instructions.

Frequently Asked Questions About CJC-1295 With DAC 2mg

What is CJC-1295 With DAC 2mg?

It is a product listing for a synthetic long-acting GHRH analogue with a labelled quantity of 2mg.

What does DAC mean in CJC-1295?

DAC stands for Drug Affinity Complex, referring to the albumin-binding chemical modification.

How many amino acids are in CJC-1295 with DAC?

The underlying modified GHRH peptide contains 29 amino acid residues.

What is the molecular weight of CJC-1295 with DAC?

The commonly described DAC-modified construct has an approximate molecular weight of 3,647 g/mol. The exact supplied molecular form should be verified.

What is the half-life of CJC-1295 with DAC?

Published human research reported an estimated elimination half-life of approximately 5.8–8.1 days for the investigated preparation.

Is CJC-1295 with DAC the same as without DAC?

No. The with-DAC form contains an albumin-binding modification absent from Modified GRF 1-29.

What receptor does CJC-1295 with DAC target?

It is associated with the growth hormone-releasing hormone receptor, GHRHR.

Does CJC-1295 with DAC increase growth hormone?

Controlled human research reported sustained increases in circulating growth hormone following exposure to the investigated DAC-modified compound.

Does CJC-1295 with DAC increase IGF-1?

Published human studies reported increased IGF-1 concentrations under specific experimental conditions.

Does CJC-1295 with DAC build muscle?

There is insufficient reliable clinical evidence demonstrating sustained increases in muscle mass or strength.

Is CJC-1295 with DAC a weight-loss peptide?

No. It is not an established treatment for obesity or weight management.

Is CJC-1295 with DAC approved for medical use?

It is not an established approved medicine for weight loss, muscle growth or anti-ageing treatment in the United Kingdom.

What does the 2mg designation mean?

It refers to the labelled quantity of research material, not a recommended human dose.

CJC-1295 With DAC 2mg – Product Summary

CJC-1295 With DAC 2mg is a synthetic long-acting growth hormone-releasing hormone analogue investigated in endocrine and peptide pharmacokinetic research.

Its albumin-binding DAC modification distinguishes it from Modified GRF 1-29 and is associated with prolonged systemic exposure in published human studies.

Although research has demonstrated sustained changes in growth hormone and IGF-1 concentrations, long-term safety and clinical therapeutic effectiveness remain unestablished.

Researchers should verify the exact molecular identity, DAC modification, purity, salt form, labelled quantity and batch-specific documentation before selecting CJC-1295 With DAC 2mg for laboratory investigation.